Intervention Protocol

You have full text access to this OnlineOpen article

Isoprinosine versus other antiviral drugs for chronic hepatitis B

  1. Basile Njei1,*,
  2. Sushil Kumar Garg2,
  3. Emmanuel Kenta-Bibi3,
  4. Pan Zhao4,
  5. Eugene J Kongnyuy5

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010506

How to Cite

Njei B, Garg SK, Kenta-Bibi E, Zhao P, Kongnyuy EJ. Isoprinosine versus other antiviral drugs for chronic hepatitis B (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010506. DOI: 10.1002/14651858.CD010506.

Author Information

  1. 1

    University of Connecticut School of Medicine, Department of Medicine, Farmington, Connecticut, USA

  2. 2

    University of Minnesota, Department of Surgery, Minneapolis, USA

  3. 3

    Faculty, Middlesex Hospital Family Practice Residency, UCONN, Portland, Oregon, USA

  4. 4

    Beijing 302 Hospital, Liver Failure Therapy and Research Center, Beijing, China

  5. 5

    Reproductive Health Solutions, Salisbury, UK

*Basile Njei, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut, 06030, USA. basilenjei@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the benefits and harms of isoprinosine in the treatment of patients with chronic HBV infection.